ANDA 202881, held by Mylan Institutional. Dexmedetomidine Hydrochloride.
As of Nov 22, 2026, ANDA 202881 (Dexmedetomidine Hydrochloride), held by Mylan Institutional, was first approved by FDA on Aug 18, 2014, with 4 approved supplements and 0 published complete response letters.
Dexmedetomidine injection is an alpha 2 -adrenergic receptor agonist indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 18, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dexmedetomidine HydrochlorideEQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) · injectable;injection | Dexmedetomidine Hydrochloride | Rx |
| May 26, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 26, 2020 | Supplement 7Labeling · Standard review | Approved | None posted |
| May 26, 2020 | Supplement 8Labeling · Standard review | Approved | None posted |
| May 26, 2020 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 18, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters